GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cell Source Inc (OTCPK:CLCS) » Definitions » Cyclically Adjusted PB Ratio

Cell Source (Cell Source) Cyclically Adjusted PB Ratio : (As of May. 23, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Cell Source Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cell Source Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Cell Source's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cell Source Cyclically Adjusted PB Ratio Chart

Cell Source Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cell Source Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cell Source's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Cell Source's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cell Source's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cell Source's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cell Source's Cyclically Adjusted PB Ratio falls into.



Cell Source Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Cell Source's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Cell Source's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book=Book Value per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.416/129.8595*129.8595
=-0.416

Current CPI (Sep. 2023) = 129.8595.

Cell Source Quarterly Data

Book Value per Share CPI Adj_Book
201312 -0.093 98.326 -0.123
201403 0.000 99.695 0.000
201406 -0.072 100.560 -0.093
201409 -0.094 100.428 -0.122
201412 -0.160 99.070 -0.210
201503 -0.184 99.621 -0.240
201506 -0.208 100.684 -0.268
201509 -0.234 100.392 -0.303
201512 -0.241 99.792 -0.314
201603 -0.274 100.470 -0.354
201606 -0.302 101.688 -0.386
201609 -0.320 101.861 -0.408
201612 -0.256 101.863 -0.326
201703 -0.225 102.862 -0.284
201706 -0.213 103.349 -0.268
201709 -0.225 104.136 -0.281
201712 -0.180 104.011 -0.225
201803 -0.210 105.290 -0.259
201806 -0.229 106.317 -0.280
201809 -0.235 106.507 -0.287
201812 -0.189 105.998 -0.232
201903 -0.196 107.251 -0.237
201906 -0.195 108.070 -0.234
201909 -0.223 108.329 -0.267
201912 -0.212 108.420 -0.254
202003 -0.229 108.902 -0.273
202006 -0.220 108.767 -0.263
202009 -0.234 109.815 -0.277
202012 -0.244 109.897 -0.288
202103 -0.277 111.754 -0.322
202106 -0.301 114.631 -0.341
202109 -0.303 115.734 -0.340
202112 -0.286 117.630 -0.316
202203 -0.290 121.301 -0.310
202206 -0.306 125.017 -0.318
202209 -0.339 125.227 -0.352
202212 -0.350 125.222 -0.363
202303 -0.382 127.348 -0.390
202306 -0.392 128.729 -0.395
202309 -0.416 129.860 -0.416

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cell Source  (OTCPK:CLCS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Cell Source Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Cell Source's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cell Source (Cell Source) Business Description

Traded in Other Exchanges
N/A
Address
57 West 57th Street, Suite 400, New York, NY, USA, 10019
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. Its other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched and mismatched organ transplantation.
Executives
George Verstraete director 341 LAKEWOOD DRIVE, BLOOMFIELD HILLS MI 48304
Darlene Soave director, 10 percent owner 341 LAKEWOOD DRIVE, BLOOMFIELD HILLS MI 48304
Yair Reisner 10 percent owner
Yoram Drucker director 31 DOV SADAN ST., JERUSALEM L3 97844
Dennis M Brown director 100 SAN MATEO DR, MENLO PARK CA 94025
Itamar Shimrat director, officer: CEO and CFO C/O CELL SOURCE, INC., 65 YIGAL ALON STREET, TEL AVIV L3 67433
David Zolty director C/O CELL SOURCE, INC., 65 YIGAL ALON STREET, TEL AVIV L3 67433
Benzion Abraham Friedman director, 10 percent owner C/O CELL SOURCE INC, 65 YIGALL ALON STREET, TEL AVIV L3 67433

Cell Source (Cell Source) Headlines